See the DrugPatentWatch profile for Valbenazine
Valbenazine Dosing for Tardive Dyskinesia
The recommended starting dose for valbenazine (Ingrezza) for tardive dyskinesia is 40 mg once daily [1]. After one week, this can be increased to a target dose of 80 mg once daily [1]. Some individuals may benefit from a dose of 120 mg once daily, which can be achieved by increasing the dose by 40 mg increments weekly, not to exceed 120 mg per day [1].
How Long Does It Take for Valbenazine to Work?
The full therapeutic effect of valbenazine may not be apparent for up to four weeks [1]. Clinical studies have shown statistically significant reductions in tardive dyskinesia symptoms by week four of treatment [2].
Can Valbenazine Be Adjusted Based on Patient Response?
Dosing adjustments for valbenazine are based on individual patient response and tolerability [1]. Physicians can titrate the dose upwards to a maximum of 120 mg per day if needed, or downwards if side effects occur [1].
What Factors Influence Valbenazine Dosage?
Factors such as age, liver function, and potential drug interactions can influence valbenazine dosage [1]. For patients with moderate to severe hepatic impairment, the maximum recommended dose is 60 mg once daily [1].
Are There Specific Dosing Considerations for Certain Populations?
For elderly patients or those with mild to moderate hepatic impairment, no dosage adjustment is typically required [1]. However, caution and dose adjustments may be necessary when co-administered with strong CYP3A4 inhibitors or inducers [1].
What Are the Side Effects Associated with Valbenazine Dosing?
The most common side effects reported with valbenazine include somnolence, dry mouth, and constipation [1]. Dose-related increases in somnolence have been observed [1].
When Does Valbenazine Patent Expiry Occur?
Valbenazine (Ingrezza) has patent protection that influences its market exclusivity [3]. Specific patent expiry dates can be complex and subject to various challenges and extensions [3]. Information on patent timelines for specific drugs is available through resources like DrugPatentWatch.com [3].
---
Sources:
1. Ingrezza Prescribing Information
2. Factor et al., 2015
3. DrugPatentWatch.com